FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Among patients with metastatic pancreatic cancer, combination chemotherapy with fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) leads to longer overall survival than gemcitabine therapy. We compared the efficacy and safety of a modified FOLFIRINOX regimen with gemcitabine as adjuvant therapy in patients with resected pancreatic cancer. METHODS: We randomly assigned 493 patients with resected pancreatic ductal adenocarcinoma to receive a modified FOLFIRINOX regimen (oxaliplatin [85 mg per square meter of body-surface area], irinotecan [180 mg per square meter, reduced to 150 mg per square meter after a protocol-specified safety analysis], leucovorin [400 mg per square meter], and fluorouracil [2400 mg per square meter] every 2 weeks) or gemcitabine (1000 mg per square meter on days 1, 8, and 15 every 4 weeks) for 24 weeks. The primary end point was disease-free survival. Secondary end points included overall survival and safety. RESULTS: At a median follow-up of 33.6 months, the median disease-free survival was 21.6 months in the modified-FOLFIRINOX group and 12.8 months in the gemcitabine group (stratified hazard ratio for cancer-related event, second cancer, or death, 0.58; 95% confidence interval [CI], 0.46 to 0.73; P<0.001). The disease-free survival rate at 3 years was 39.7% in the modified-FOLFIRINOX group and 21.4% in the gemcitabine group. The median overall survival was 54.4 months in the modified-FOLFIRINOX group and 35.0 months in the gemcitabine group (stratified hazard ratio for death, 0.64; 95% CI, 0.48 to 0.86; P=0.003). The overall survival rate at 3 years was 63.4% in the modified-FOLFIRINOX group and 48.6% in the gemcitabine group. Adverse events of grade 3 or 4 occurred in 75.9% of the patients in the modified-FOLFIRINOX group and in 52.9% of those in the gemcitabine group. One patient in the gemcitabine group died from toxic effects (interstitial pneumonitis). CONCLUSIONS: Adjuvant therapy with a modified FOLFIRINOX regimen led to significantly longer survival than gemcitabine among patients with resected pancreatic cancer, at the expense of a higher incidence of toxic effects. (Funded by R&D Unicancer and others; ClinicalTrials.gov number, NCT01526135 ; EudraCT number, 2011-002026-52 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Polychemotherapy, either with 5-fluorouracil (5-FU), irinotecan and oxaliplatin in combination with folinic acid (FOLFIRINOX), or with gemcitabine and nab-paclitaxel (GnP), is considered the standard of care for patients suffering from metastatic PDAC (mPDAC)3,4.”
From Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer (2023) · cites this paper as [4]
In the citing paper
“Less than half of all patients respond to the primary treatment for PDAC, chemotherapy3,4”
From Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer (2023) · cites this paper as [4]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Siegel, R. L., Miller, K. D., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21442 · Cited by 16,579
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810
Self-citationRahib, L., Smith, B. D., Aizenberg, R., Rosenzweig, A. B., Fleshman, J. M., & Matrisian, L. M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0155 · Cited by 7,094
TNM Classification of Malignant Tumors
Carter, D. (1998) · The American Journal of Surgical Pathology · doi:10.1097/00000478-199810000-00016 · Cited by 6,330
Proportional hazards tests and diagnostics based on weighted residuals
GRAMBSCH, P. M., & THERNEAU, T. M. (1994) · Biometrika · doi:10.1093/biomet/81.3.515 · Cited by 5,885
A Randomized Trial of Chemoradiotherapy and Chemotherapy after Resection of Pancreatic Cancer
Neoptolemos, J. P., Stocken, D. D., Friess, H., Bassi, C., Dunn, J. A., Hickey, H., Beger, H., Fernandez-Cruz, L., Dervenis, C., Lacaine, F., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032295 · Cited by 2,716
Oettle, H., Post, S., Neuhaus, P., Gellert, K., Langrehr, J., Ridwelski, K., Schramm, H., Fahlke, J., Zuelke, C., Burkart, C., et al. (2007) · JAMA · doi:10.1001/jama.297.3.267 · Cited by 2,419
Neoptolemos, J. P., Palmer, D. H., Ghaneh, P., Psarelli, E. E., Valle, J. W., Halloran, C. M., Faluyi, O., O'Reilly, D. A., Cunningham, D., Wadsley, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32409-6 · Cited by 1,926
Self-citationOettle, H., Neuhaus, P., Hochhaus, A., Hartmann, J. T., Gellert, K., Ridwelski, K., Niedergethmann, M., Zülke, C., Fahlke, J., Arning, M. B., et al. (2013) · JAMA · doi:10.1001/jama.2013.279201 · Cited by 1,794
Research works printed but not linked: 1
- Early Breast Cancer Trialists’ Collaborative Group. Treatment of early breast cancer. Vol. 1. Worldwide evidence 1985–1990. Oxford England: Oxford University Press 1990.
Cited by
Items 101–200 of 1,002
Neoadjuvant Treatment in Patients With Resectable and Borderline Resectable Pancreatic Cancer
Janssen, Q. P., O'Reilly, E. M., van Eijck, C. H. J., & Koerkamp, B. G. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00041 · Cited by 139
Pancreatic Ductal Adenocarcinoma and Its Variants: Pearls and Perils
Schawkat, K., Manning, M. A., Glickman, J. N., & Mortelé, K. J. (2020) · Radiographics · doi:10.1148/rg.2020190184 · Cited by 124
Zhou, X., Han, J., Zuo, A., Ba, Y., Liu, S., Xu, H., Zhang, Y., Weng, S., Zhou, Z., Liu, L., et al. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02180-y · Cited by 127
Zhang, C., Xin, L., Li, J., Cao, J., Sun, Y., Wang, X., Luo, J., Zeng, Y., Li, Q., Zhang, Y., et al. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202101946 · Cited by 113
Efferocytosis reprograms the tumor microenvironment to promote pancreatic cancer liver metastasis
Astuti, Y., Raymant, M., Quaranta, V., Clarke, K., Abudula, M., Smith, O., Bellomo, G., Chandran-Gorner, V., Nourse, C., Halloran, C. M., et al. (2024) · Nature Cancer · doi:10.1038/s43018-024-00731-2 · Cited by 131
“Around 70% of the patients whose primary tumor is removed relapse with hepatic metastasis within 2 years of surgery 4 .”
The role of microbial indole metabolites in tumor
Jia, D., Kuang, Z., & Wang, L. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2409209 · Cited by 116
“42 Although tumor markers such as CA19–9 have been shown to be useful in predicting the efficacy of response to chemotherapy, there is a lack of observables for long-term response.”
BackgroundVarghese, A. M., Perry, M., Chou, J. F., Nandakumar, S., Muldoon, D. M., Erakky, A., Zucker, A., Fong, C. J., Mehine, M. M., Nguyen, B., et al. (2025) · Nature Medicine · doi:10.1038/s41591-024-03362-3 · Cited by 144
“Treatment selection reflected changes in standard-of-care guidelines over the course of the study 54 .”
Self-citationUnno, M., Motoi, F., Matsuyama, Y., Satoi, S., Toyama, H., Matsumoto, I., Aosasa, S., Shirakawa, H., Wada, K., Fujii, T., et al. (2025) · Annals of Surgery · doi:10.1097/sla.0000000000006730 · Cited by 134
Koltai, T., Reshkin, S. J., Carvalho, T. M. A., Molfetta, D. D., Greco, M. R., Alfarouk, K. O., & Cardone, R. A. (2022) · Cancers · doi:10.3390/cancers14102486 · Cited by 132
“The FOLFIRINOX scheme (folinic acid/5-FU/irinotecan/oxaliplatin) has been found somewhat more effective, but at the price of high toxicity [32,33].”
BackgroundPeng, Y.-C., Wu, C., Tien, Y., Lu, T., Wang, Y.-H., & Chen, B. (2020) · European Radiology · doi:10.1007/s00330-020-07294-7 · Cited by 110
Pishvaian, M. J., Blais, E. M., Brody, J. R., Rahib, L., Lyons, E. E., Arbeloa, P., Hendifar, A. E., Mikhail, S., Chung, V. M., Sohal, D. P. S., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.19.00115 · Cited by 110
Xie, C., Duffy, A. G., Brar, G. S., Fioravanti, S., Mabry‐Hrones, D., Walker, M., Bonilla, C. M., Wood, B. J., Citrin, D. E., Ramirez, E. M. G., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3624 · Cited by 107
Beyer, G., Hoffmeister, A., Michl, P., Gress, T. M., Huber, W., Algül, H., Neeße, A., Meining, A. G., Seufferlein, T. T. W., Rosendahl, J., et al. (2022) · Zeitschrift für Gastroenterologie · doi:10.1055/a-1735-3864 · Cited by 128
SMAD4 and the TGFβ Pathway in Patients with Pancreatic Ductal Adenocarcinoma
Dardare, J., Witz, A., Merlin, J.-L., Gilson, P., & Harlé, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103534 · Cited by 101
Hewitt, D. B., Nissen, N., Hatoum, H., Musher, B., Seng, J., Coveler, A. L., Al-Rajabi, R., Yeo, C. J., Leiby, B., Banks, J., et al. (2020) · Annals of Surgery · doi:10.1097/sla.0000000000004669 · Cited by 110
Perri, G., Prakash, L., Wang, H., Bhosale, P., Varadhachary, G. R., Wolff, R. A., Fogelman, D. R., Overman, M. J., Pant, S., Javle, M. M., et al. (2019) · Annals of Surgery · doi:10.1097/sla.0000000000003442 · Cited by 102
Heumann, T. R., Judkins, C., Li, K., Lim, S. J., Hoare, J., Parkinson, R. M., Cao, H., Zhang, T., Gai, J., Celiker, B., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39196-9 · Cited by 104
Neoadjuvant Chemotherapy in Pancreatic Cancer: An Appraisal of the Current High-Level Evidence
Müller, P. C., Frey, M. C., Ruzza, C. M., Nickel, F., Jost, C., Gwerder, C., Hackert, T., Z’graggen, K., & Kessler, U. (2020) · Pharmacology · doi:10.1159/000510343 · Cited by 97
Targeting KRAS in pancreatic cancer
Stickler, S., RATH, B., & Hamilton, G. (2024) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2024.045356 · Cited by 118
“…Gemcitabine, for pancreatic cancer patients has been replaced by modi fi ed FOLFIRINOX (mFOLFIRINOX) (5-fl uorouracil, leucovorin, oxaliplatin and irinotecan) or nab-paclitaxel plus gemcitabine therapies but these regimens provide only modest survival in presence of high toxicity [9,10].”
Consensus, debate, and prospective on pancreatic cancer treatments
Wang, J., Yang, J., Narang, A. K., He, J., Wolfgang, C. L., Li, K., & Zheng, L. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01613-x · Cited by 109
Stroma-Targeting Therapy in Pancreatic Cancer: One Coin With Two Sides?
Jiang, B., Zhou, L., Lu, J., Wang, Y., Liu, C., You, L., & Guo, J. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.576399 · Cited by 93
“, 5fluorouracil, leucovorin, oxaliplatin, and irinotecan) (6).”
Ampullary Adenocarcinoma, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology
Chiorean, E. G., Chiaro, M. D., Tempero, M. A., Malafa, M. P., Benson, A. B., Cardin, D. B., Christensen, J. A., Chung, V. M., Czito, B. G., Dillhoff, M. E., et al. (2023) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2023.0034 · Cited by 122
“159 In this study, 493 patients with pancreatic cancer were randomly assigned to receive mFOLFIRINOX (n 5 247) or gemcitabine (n 5 246) postoperatively.”
MethodSeppälä, T. T., Zimmerman, J. W., Suri, R., Zlomke, H., Ivey, G. D., Szabolcs, A., Shubert, C. R., Cameron, J. L., Burns, W. R., Lafaro, K. J., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-4165 · Cited by 111
Neoadjuvant therapy for pancreatic cancer
Gugenheim, J., Crovetto, A., & Petrucciani, N. (2021) · Updates in Surgery · doi:10.1007/s13304-021-01186-1 · Cited by 108
Personalized pancreatic cancer therapy: from the perspective of mRNA vaccine
Huang, X., Zhang, G., Tang, T., Gao, X., & Liang, T. (2022) · Military Medical Research · doi:10.1186/s40779-022-00416-w · Cited by 121
GPT-4 for Information Retrieval and Comparison of Medical Oncology Guidelines
Ferber, D., Wiest, I. C., Wölflein, G., Ebert, M. P., Beutel, G., Eckardt, J.-N., Truhn, D., Springfeld, C., Jäger, D., & Kather, J. N. (2024) · NEJM AI · doi:10.1056/aics2300235 · Cited by 92
Frère, C., Bournet, B., Gourgou, S., Fraisse, J., Canivet, C., Connors, J. M., Buscail, L., Farge, D., Bournet, B., Canivet, C., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.12.009 · Cited by 104
Self-citationPrognosis Based Definition of Resectability in Pancreatic Cancer: A Road Map to New Guidelines
Oba, A., Croce, C., Hosokawa, P., Meguid, C., Torphy, R. J., Al-Musawi, M. H., Ahrendt, S., Gleisner, A., Schulick, R. D., & Chiaro, M. D. (2020) · Annals of Surgery · doi:10.1097/sla.0000000000003859 · Cited by 100
Nanotechnology in medicine revolutionizing drug delivery for cancer and viral infection treatments
Sher, E. K., Alebić, M., Boras, M. M., Boškailo, E., Farhat, E. K., Karahmet, A., Pavlović, B., Sher, F., & Lekić, L. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.124345 · Cited by 119
Chan, K., Guo, H., Cheng, S., Beca, J. M., Redmond‐Misner, R., Isaranuwatchai, W., Qiao, L., Earle, C. C., Berry, S. R., Biagi, J., et al. (2019) · Cancer Medicine · doi:10.1002/cam4.2705 · Cited by 95
Self-citationPancreatic circulating tumor cell profiling identifies LIN28B as a metastasis driver and drug target
Franses, J. W., Philipp, J., Missios, P., Bhan, I., Liu, A., Yashaswini, C. N., Tai, E. C., Zhu, H., Ligorio, M., Nicholson, B., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17150-3 · Cited by 93
Oxaliplatin and its derivatives – An overview
O'Dowd, P., Sutcliffe, D. F., & Griffith, D. M. (2023) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2023.215439 · Cited by 103
ESMO Management and treatment adapted recommendations in the COVID-19 era: Pancreatic Cancer
Catanese, S., Pentheroudakis, G. E., Douillard, J.-Y., & Lordick, F. (2020) · ESMO Open · doi:10.1136/esmoopen-2020-000804 · Cited by 93
Tumour budding and its clinical implications in gastrointestinal cancers
Zlobec, I., Berger, M. D., & Lugli, A. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0954-z · Cited by 102
A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma
Nicolle, R., Gayet, O., Duconseil, P., Vanbrugghe, C., Roques, J., Bigonnet, M., Blum, Y., Elarouci, N., Armenoult, L., Ayadi, M., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.10.601 · Cited by 112
“It would be of high interest to assess the predictive value of the GemPred signature in patients included in the PRODIGE24 phase III randomized trial that compared mFOLFIRINOX with gemcitabine in the adjuvant setting.(6) This work entails further investigations to establish its clinical applicability.”
MethodSelf-citationNeoadjuvant Therapy for Resectable Pancreatic Cancer
Birrer, D. L., Golcher, H., Casadei, R., Haile, S. R., Fritsch, R., Hussung, S., Brunner, T. B., Fietkau, R., Meyer, T., Grützmann, R., et al. (2021) · Annals of Surgery · doi:10.1097/sla.0000000000005126 · Cited by 100
“Additional evidence came with improved DFS, OS, and metastasis-free survivals, when using adjuvant mFolfirinoxGe (modified folinic acid, 5-FU, irinotecan, oxaliplatin, gemcitabine) compared to gemcitabine alone.(8) A constant limitation of adjuvant chemotherapy has remained in the inability to start treatment in more…”
MethodPancreatic Adenocarcinoma Management
Jiang, Y., & Sohal, D. P. S. (2022) · JCO Oncology Practice · doi:10.1200/op.22.00328 · Cited by 107
Okusaka, T., & Furuse, J. (2020) · Journal of Gastroenterology · doi:10.1007/s00535-020-01666-y · Cited by 98
Yang, J., Yu, X., Xiao, M., He, X., Tan, Z., Lei, Y., Guo, Y., Wang, W., Xu, J., Shi, S., et al. (2025) · Gut · doi:10.1136/gutjnl-2024-334361 · Cited by 122
Petrelli, F., Zaniboni, A., Ghidini, A., Ghidini, M., Turati, L., Pizzo, C., Ratti, M., Libertini, M., & Tomasello, G. (2019) · Cancers · doi:10.3390/cancers11040550 · Cited by 87
Murthy, P., Zenati, M. S., Abbas, A. I. A., Rieser, C. J., Bahary, N., Lotze, M. T., Zeh, H. J., Zureikat, A. H., & Boone, B. A. (2019) · Annals of Surgical Oncology · doi:10.1245/s10434-019-08094-0 · Cited by 93
Eshmuminov, D., Aminjonov, B., Palm, R. F., Malleo, G., Schmocker, R. K., Abdallah, R., Yoo, C., Shaib, W. L., Schneider, M. A., Rangelova, E. B., et al. (2023) · Annals of Surgical Oncology · doi:10.1245/s10434-023-13353-2 · Cited by 98
“care.(7,39,40) In contrast to primary, resectable pancreatic cancer, data suggest that patients with BRPC or LAPC have improved outcomes when treated with primary chemotherapy with or without radiotherapy.”
BackgroundAdjuvant treatment for pancreatic cancer
Klaiber, U., Hackert, T., & Neoptolemos, J. P. (2019) · Translational Gastroenterology and Hepatology · doi:10.21037/tgh.2019.04.04 · Cited by 85
Ma, S. J., Oladeru, O. T., Miccio, J. A., Iovoli, A. J., Hermann, G. M., & Singh, A. K. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.9126 · Cited by 92
Golan, T., Barenboim, A., Lahat, G., Nachmany, I., Goykhman, Y., Shacham‐Shmueli, E., Halpern, N., Brazowski, E., Geva, R., Wolf, I., et al. (2020) · Annals of Surgical Oncology · doi:10.1245/s10434-020-08469-8 · Cited by 82
Xin, X., Kumar, V., Lin, F., Kumar, V., Bhattarai, R. S., Bhatt, V. R., Tan, C., & Mahato, R. I. (2020) · Science Advances · doi:10.1126/sciadv.abd6764 · Cited by 81
Hirt, C., Booij, T. H., Grob, L., Simmler, P., Toussaint, N. C., Keller, D., Taube, D., Ludwig, V., Goryachkin, A., Pauli, C., et al. (2022) · Cell Genomics · doi:10.1016/j.xgen.2022.100095 · Cited by 109
Hank, T. P., Klaiber, U., Hinz, U., Schütte, D., Leonhardt, C.-S., Bergmann, F., Hackert, T., Jäger, D., Büchler, M. W., & Strobel, O. (2022) · Annals of Surgery · doi:10.1097/sla.0000000000005481 · Cited by 92
Iron-Sensitive Prodrugs That Trigger Active Ferroptosis in Drug-Tolerant Pancreatic Cancer Cells
Antoszczak, M., Müller, S., Cañeque, T., Colombeau, L., Dusetti, N., Santofimia‐Castaño, P., Gaillet, C., Puisieux, A., Iovanna, J., & Rodriguez, R. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.2c03973 · Cited by 82
Digestive cancers: mechanisms, therapeutics and management
Zhan, T., Betge, J., Schulte, N., Dreikhausen, L., Hirth, M., Li, M., Weidner, P., Leipertz, A., Teufel, A., & Ebert, M. P. A. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02097-4 · Cited by 100
Organoid models for translational pancreatic cancer research
Tiriac, H., Plenker, D., Baker, L. A., & Tuveson, D. A. (2019) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2019.02.003 · Cited by 79
Gu, Z., Du, Y., Zhao, X., & Wang, C. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.08.029 · Cited by 84
Ashrafizadeh, M., Zhang, W., Zou, R., Sethi, G., Klionsky, D. J., & Zhang, X. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106822 · Cited by 79
Okada, Y., Takahashi, N., Takayama, T., & Goel, A. (2021) · Carcinogenesis · doi:10.1093/carcin/bgab011 · Cited by 87
Clinical Impact of Molecular Subtyping of Pancreatic Cancer
Zhou, X., Hu, K., Bailey, P. J., Springfeld, C., Roth, S., Kurilov, R., Brors, B., Gress, T. M., Buchholz, M., An, J., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.743908 · Cited by 87
Molecular mediators of peritoneal metastasis in pancreatic cancer
Avula, L. R., Hagerty, B. L., & Alewine, C. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09924-4 · Cited by 83
Targeting the Hypoxic and Acidic Tumor Microenvironment with pH-Sensitive Peptides
Dharmaratne, N. U., Kaplan, A. R., & Glazer, P. M. (2021) · Cells · doi:10.3390/cells10030541 · Cited by 78
“These drugs are an essential component of chemotherapy in the treatment of a number of cancers, and the topoisomerase inhibitor irinotecan has shown promising results when used in combination with oxaliplatin and 5-FU in pancreatic cancer [66].”
BackgroundLeonhardt, C.-S., Gustorff, C., Klaiber, U., Blanc, S. L., Stamm, T. A., Verbeke, C. S., Prager, G. W., & Strobel, O. (2024) · Gastroenterology · doi:10.1053/j.gastro.2024.05.028 · Cited by 89
Liquid Biopsy Approach for Pancreatic Ductal Adenocarcinoma
Buscail, E., Maulat, C., Muscari, F., Chiche, L., Cordelier, P., Dabernat, S., Alix-Panabières, C., & Buscail, L. (2019) · Cancers · doi:10.3390/cancers11060852 · Cited by 74
Huerta, M., Roselló, S., Sabater-Orti, L., Ferrer, A., Tarazona, N., Roda, D., Gambardella, V., Alfaro‐Cervelló, C., Garcés‐Albir, M., Cervantes, A. M. R., et al. (2021) · Cancers · doi:10.3390/cancers13050994 · Cited by 83
Liu, X., Jiang, J., Chang, C. H., Liao, Y., Lodico, J. J., Tang, I., Zheng, E., Qiu, W., Lin, M. J., Wang, X., et al. (2021) · Small · doi:10.1002/smll.202005993 · Cited by 81
The Role of Imaging in Current Treatment Strategies for Pancreatic Adenocarcinoma
Rhee, H., & Park, M. (2020) · Korean Journal of Radiology · doi:10.3348/kjr.2019.0862 · Cited by 84
“According to two recent clinical trials, patients treated with combination chemotherapies, including modified 5-FU/leucovorin, oxaliplatin, and irinotecan (FOLFIRINOX) or gemcitabine + capecitabine, showed significantly better overall survival than those treated with gemcitabine monotherapy (15, 16).”
BackgroundBRCA mutated pancreatic cancer: A change is coming
Rosen, M. N., Goodwin, R. A., & Vickers, M. M. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i17.1943 · Cited by 88
Overcoming Gemcitabine Resistance in Pancreatic Cancer Using the BCL-XL–Specific Degrader DT2216
Thummuri, D., Khan, S. U., Underwood, P. W., Zhang, P., Wiegand, J. S., Zhang, X., Budamagunta, V., Sobh, A., Tagmount, A., Loguinov, A., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0474 · Cited by 75
Innominato, P. F., Ballesta, A., Huang, Q., Focan, C., Chollet, P. J. M., Karaboué, A., Giacchetti, S., Bouchahda, M., Adam, R. A., Garufi, C., et al. (2020) · Cancer Medicine · doi:10.1002/cam4.3056 · Cited by 71
Karas, S., & Innocenti, F. (2021) · JCO Oncology Practice · doi:10.1200/op.21.00624 · Cited by 80
“The reduced dose for FOLFIRINOX is based on the studies demonstrating tolerability.(67,68) The reduced dose for FOLFOXIRI is based on the trial protocol dose reduction and the study demonstrating tolerability.”
Methodfor the Dutch Pancreatic Cancer Group, Latenstein, A. E. J., van Roessel, S. R., van der Geest, L. G., Bonsing, B. A., Dejong, C. H. C., Koerkamp, B. G., de Hingh, I. H. J. T., Homs, M. Y. V., Klaase, J. M., et al. (2020) · Annals of Surgical Oncology · doi:10.1245/s10434-020-08235-w · Cited by 81
Photodynamic therapy of pancreatic cancer: Where have we come from and where are we going?
Wang, Y., Wang, H., Zhou, L., Lü, J., Jiang, B., Liu, C., & Guo, J. (2020) · Photodiagnosis and Photodynamic Therapy · doi:10.1016/j.pdpdt.2020.101876 · Cited by 76
Clinical and genomic characterisation of mismatch repair deficient pancreatic adenocarcinoma
Grant, R. C., Denroche, R. E., Jang, G. H., Nowak, K. M., Zhang, A. X. W., Borgida, A., Holter, S., Topham, J. T., Wilson, J. M., Dodd, A., et al. (2020) · Gut · doi:10.1136/gutjnl-2020-320730 · Cited by 79
Law, H. C.-H., Lagundžin, D., Clement, E. J., Qiao, F., Wagner, Z. S., Krieger, K. L., Costanzo-Garvey, D. L., Caffrey, T. C., Grem, J. L., DiMaio, D. J., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1496 · Cited by 75
Wu, C., Tan, X., Hu, X., Zhou, M., Yan, J., & Ding, C. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.1900930 · Cited by 72
Palmer, D. H., Valle, J. W., Ma, Y. T., Faluyi, O. O., Neoptolemos, J. P., Gjertsen, T. J., Iversen, B., Eriksen, J. A., Møller, A. W., Aksnes, A.-K., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0752-7 · Cited by 70
Jiang, X., Lee, M. J., Xia, J., Luo, T., Liu, J., Rodriguez, M., & Lin, W. (2022) · ACS Nano · doi:10.1021/acsnano.2c09788 · Cited by 70
Liquid Biopsy in Pancreatic Cancer: Are We Ready to Apply It in the Clinical Practice?
Heredia-Soto, V., Rodríguez-Salas, N., & Feliú, J. (2021) · Cancers · doi:10.3390/cancers13081986 · Cited by 81
“In resectable PDAC they are detected in up to 60% of patients during the three years following surgery [7], and in borderline cases in 80% of patients in the first year after the surgical process [135].”
BackgroundInfluentialCai, H., Wang, R., Guo, X., Song, M., Yan, F., Ji, B., & Liu, Y. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c01225 · Cited by 73
Reshaping preoperative treatment of pancreatic cancer in the era of precision medicine
Casolino, R., Braconi, C., Malleo, G., Paiella, S., Bassi, C., Milella, M., Dreyer, S. B., Froeling, F. E. M., Chang, D. K.-F., Biankin, A. V., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.11.013 · Cited by 74
“5-fluorouracil, leucovorin, oxaliplatin, and irinotecan) likely adds modest survival benefit in all-comers at the expense of a considerable toxicity.(7) The reasons for these poor outcomes stem from the inherent aggressiveness of PC, that lends it to be defined as ‘metastatic ab-initio’ disease, irrespective of the cl…”
BackgroundNeoadjuvant Chemotherapy Switch in Borderline Resectable/Locally Advanced Pancreatic Cancer
Alva‐Ruiz, R., Yohanathan, L., Yonkus, J. A., Abdelrahman, A. M., Gregory, L. A., Halfdanarson, T. R., Mahipal, A., McWilliams, R. R., Ma, W. W., Hallemeier, C. L., et al. (2021) · Annals of Surgical Oncology · doi:10.1245/s10434-021-10991-2 · Cited by 76
Habib, J. R., Kinny‐Köster, B., van Oosten, F., Javed, A. A., Cameron, J. L., Lafaro, K. J., Burkhart, R. A., Burns, W. R., He, J. P., Thompson, E. D., et al. (2020) · Surgery · doi:10.1016/j.surg.2020.08.031 · Cited by 74
Pilot Study Experiences With Hyperpolarized [1‐ 13 C]pyruvate MRI in Pancreatic Cancer Patients
Stødkilde‐Jørgensen, H., Laustsen, C., Hansen, E. S. S., Schulte, R. F., Ardenkjær‐Larsen, J. H., Comment, A., Frøkiær, J., Ringgaard, S., Bertelsen, L. B., Ladekarl, M. B., et al. (2019) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.26888 · Cited by 72
Recent advances in the treatment of pancreatic cancer
Roth, M. T., Cardin, D. B., & Berlin, J. D. (2020) · F1000Research · doi:10.12688/f1000research.21981.1 · Cited by 66
Weniger, M., Hank, T. P., Qadan, M., Ciprani, D., Michelakos, T. P., Niess, H., Heiliger, C., Ilmer, M., D’Haese, J. G., Ferrone, C. R., et al. (2020) · British journal of surgery · doi:10.1002/bjs.12003 · Cited by 78
Daamen, L. A., Groot, V. P., Besselink, M. G., Bosscha, K. P., Busch, O. R., Cirkel, G. A., van Dam, R. M., Festen, S., Koerkamp, B. G., Mohammad, N. H., et al. (2020) · Annals of Surgery · doi:10.1097/sla.0000000000004093 · Cited by 84
Taïeb, J., Prager, G. W., Melisi, D., Westphalen, C. B., D’Esquermes, N., Ferreras, A., Carrato, A., & Macarulla, T. M. (2020) · ESMO Open · doi:10.1136/esmoopen-2019-000587 · Cited by 72
Abrams, R. A., Winter, K. A., Safran, H. P., Goodman, K. A., Regine, W. F., Berger, A. C., Gillin, M. T., Philip, P. A., Lowy, A. M., Wu, A. J.-C., et al. (2020) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000633 · Cited by 66
Chiorean, E. G., Cheung, W. Y., Giordano, G., Kim, G., & Al-Batran, S. E. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919850367 · Cited by 66
Immunotherapy in Pancreatic Adenocarcinoma: Beyond “Copy/Paste”
Hester, R., Mazur, P. K., & McAllister, F. M. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0900 · Cited by 74
Lau, S. P., Klaase, L., Vink, M., Dumas, J., Bezemer, K., van Krimpen, A., van der Breggen, R., Wismans, L. V., Doukas, M., de Koning, W., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.03.015 · Cited by 68
Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC
Zhou, X., An, J., Kurilov, R., Brors, B., Hu, K., Peccerella, T., Roessler, S. K., Pfütze, K., Schulz, A., Wolf, S., et al. (2023) · Nature Cancer · doi:10.1038/s43018-023-00628-6 · Cited by 84
Improving outcomes of patients with pancreatic cancer
Dreyer, S. B., Beer, P. A., Hingorani, S. R., & Biankin, A. V. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01019-9 · Cited by 81
“The phase III PRODIGE 24/CCTG PA6 trial compared adjuvant FOLFIRINOX with gemcitabine monotherapy, and found a median OS of 54.4 months versus 35.0 months 21,23 (Table 1).”
InfluentialNeoadjuvant Therapy is Associated with Improved Survival in Borderline-Resectable Pancreatic Cancer
Chawla, A., Molina, G., Pak, L. M., Rosenthal, M. H., Mancias, J. D., Clancy, T. E., Wolpin, B. M., & Wang, J. (2019) · Annals of Surgical Oncology · doi:10.1245/s10434-019-08087-z · Cited by 65
Pancreatic Cancer, Gut Microbiota, and Therapeutic Efficacy
Zhang, X., Liu, Q., Liao, Q., & Zhao, Y. (2020) · Journal of Cancer · doi:10.7150/jca.37445 · Cited by 75
Early-Onset Pancreas Cancer: Clinical Descriptors, Genomics, and Outcomes
Varghese, A. M., Singh, I., Singh, R., Kunte, S., Chou, J. F., Capanu, M., Wong, W., Lowery, M. A., Stadler, Z. K., Salo‐Mullen, E. E., et al. (2021) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djab038 · Cited by 72
“and FOLFIRINOX in the adjuvant setting (2-4).”
Self-citationPalamaris, K., Felekouras, E. S., & Sakellariou, S. (2021) · Cancers · doi:10.3390/cancers13215532 · Cited by 76
Song, T., Zhang, H., Luo, Z., Shang, L., & Zhao, Y. (2023) · Advanced Science · doi:10.1002/advs.202206004 · Cited by 63
Targeting Redox Metabolism in Pancreatic Cancer
Hadi, N. A., Reyes‐Castellanos, G., & Carrier, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041534 · Cited by 68
“In contrast, for those rare patients able to undergo complete surgical resection (10–15%), the standard of care with the modified FOLFIRINOX (with a modification to exclude bolus doses of 5-fluorouracil) has provided the longest median survival (54 months) [3,22].”
BackgroundDomen, A., Quatannens, D., Zanivan, S. R., Deben, C., Audenaerde, J. R. M. V., Smits, E., Wouters, A., Lardon, F., Roeyen, G., Verhoeven, Y., et al. (2021) · Cancers · doi:10.3390/cancers13050987 · Cited by 68
Nucleoside-based anticancer drugs: Mechanism of action and drug resistance
Hrubá, L., Das, V., Hajdúch, M., & Džubák, P. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115741 · Cited by 70
Tsuchida, H., Fujii, T., Mizuma, M., Satoi, S., Igarashi, H., Eguchi, H., Kuroki, T., Shimizu, Y., Tani, M., Tanno, S., et al. (2019) · Surgery · doi:10.1016/j.surg.2019.06.023 · Cited by 64
Barnes, C. A., Chavez, M. I., Tsai, S., Aldakkak, M., George, B., Ritch, P. S., Dua, K. S., Clarke, C. N., Tolat, P. P., Hagen, C. E., et al. (2019) · Surgery · doi:10.1016/j.surg.2019.05.010 · Cited by 62
Characterization of the genomic landscape in large-scale Chinese patients with pancreatic cancer
Zhang, X., Mao, T., Zhang, B., Xu, H., Cui, J., Jiao, F., Chen, D., Wang, Y., Hu, J., Xia, Q., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.103897 · Cited by 66
Metadata
- Authors
- Conroy, T., Hammel, P., Hebbar, M., Ben Abdelghani, M., Wei, A. C., Raoul, J.-L., Choné, L., Francois, E., Artru, P., Biagi, J. J., Lecomte, T., Assenat, E., Faroux, R., Ychou, M., Volet, J., Sauvanet, A., Breysacher, G., Di Fiore, F., Cripps, C., Kavan, P., Texereau, P., Bouhier-Leporrier, K., Khemissa-Akouz, F., Legoux, J.-L., Juzyna, B., Gourgou, S., O’Callaghan, C. J., Jouffroy-Zeller, C., Rat, P., Malka, D., Castan, F., & Bachet, J.-B.
- Affiliations
- Hôpital Beaujon (FR)
- From the Institut de Cancérologie de Lorraine and Université de Lorraine (T.C.) and Centre Hospitalier Universitaire (L.C.), Nancy, Hôpital Beaujon and University Paris VII, Clichy (P.H., A.S.), Hôpital Huriez, Lille (M.H.), Centre Paul Strauss, Strasbourg (M.B.A.), Institut Paoli-Calmettes, Marseille (J.-L.R.), Centre Antoine-Lacassagne, Nice (E.F.), Hôpital Jean-Mermoz, Lyon (P.A.), Hôpital Trousseau, Tours (T.L.), Centre Hospitalier Universitaire de Saint-Eloi (E.A.) and Institut du Cancer de...
- Université de Montpellier (FR)
- Université Paris-Saclay (FR)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-12-20
- Volume
- 379
- Issue
- 25
- Pages
- 2395-2406
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2903623792
- Cited by
- 2,874
- References
- 22
- Citations by year
- 2026: 219 · 2025: 316 · 2024: 337 · 2023: 457 · 2022: 449 · 2021: 512 · 2020: 376 · 2019: 202 · 2018: 1
- FWCI
- 102.29
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Funders
- Canadian Cancer Society (Program Grant #704970)
- Institut National du Cancer (Clinical Research Hospital Program grant (PHRC11-0)
- 7 Days in May
- French National League against Cancer
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Keywords
- FOLFIRINOX, gemcitabine, adjuvant chemotherapy, pancreatic ductal adenocarcinoma, resected pancreatic cancer, disease-free survival, overall survival, oxaliplatin, irinotecan, 5-fluorouracil, leucovorin, adverse events, treatment safety, secondary malignancies, metastatic pancreatic cancer, combination chemotherapy
- MeSH terms
- Irinotecan, Oxaliplatin, Gemcitabine, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Leucovorin, Deoxycytidine, Drug Combinations, Female, Fluorouracil, Humans, Male, Middle Aged, Organometallic Compounds, Pancreatic Neoplasms, Prospective Studies, Proportional Hazards Models, Chemotherapy, Adjuvant, Lung Diseases, Interstitial, Disease-Free Survival
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.